Physician profile
Marcus Davidson
NPI 1962942839
$2,957.52
in general payments reported to CMS, 2019-2025
29 companies · $898 in 2025
The $898 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $459 · 2023: $459 · 2024: $989 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.51 | 2021-2025 | |
| Lilly USA, LLC | $245.46 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $204.23 | 2023-2025 | |
| Astellas Pharma US INC | $165.90 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $150.43 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $145.83 | 2023-2025 | Airsupra, Breztri |
| Idorsia Pharmaceuticals US INC | $99.71 | 2022-2024 | Quviviq |
| Abbott Laboratories | $94.92 | 2022-2024 | Freestyle Libre 3 |
| Acella Pharmaceuticals, LLC | $88.12 | 2022-2024 | NP Thyroid 60 |
| Revance Therapeutics, INC. | $83.00 | 2025 | Daxxify |
| Takeda Pharmaceuticals U.S.A., INC. | $82.60 | 2022-2024 | Trintellix |
| Lundbeck LLC | $76.52 | 2024-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.37 | 2023-2025 | Xifaxan, Trulance |
| Amneal Pharmaceuticals LLC | $67.38 | 2024-2025 | Unithroid |
| Novo Nordisk INC | $55.95 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.87 | 2024-2025 | Shingrix, Arexvy |
| Itamar Medical INC | $52.62 | 2024-2025 | Watchpatone |
| Tolmar, INC. | $42.54 | 2024-2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $29.47 | 2025 | Contrave, Onzetra Xsail |
| Millicent US INC | $29.10 | 2025 | Intrarosa |
| Baxter Healthcare | $25.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.69 | 2024 | Zoryve |
| Amgen INC. | $21.58 | 2023 | Repatha |
| Nestle Healthcare Nutrition INC. | $18.68 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.22 | 2022 | |
| Axsome Therapeutics, INC. | $17.79 | 2022 | |
| Ibsa Pharma INC. | $14.95 | 2024 | Licart, Tirosint |
| Teva Pharmaceuticals USA, INC. | $14.91 | 2022 | |
| Bausch Health US, LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.